Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 5:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neoplasms, Liver Clear all
Terminated Phase 1Phase 2 Interventional

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

NCT05363605
View directory record Official record
Conditions
Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma, Bladder Carcinoma, Susceptible FGFR3 Genetic Alterations, FGFR3, FGFR3 Overexpression, FGFR3 Receptor, FGFR3 Protein Overexpression, Ovarian Cancer, Colorectal Cancer, Breast Cancer, Liver Cancer, Lung Cancer, Gastric Cancer
Interventions
[225Ac]-FPI-1966, [111In]-FPI-1967, vofatamab
Drug · Biological
Lead sponsor
Fusion Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Duarte, California • San Francisco, California • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 4 Interventional Results available

Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?

NCT01101750
View directory record Official record
Conditions
Cervical Cancer, Hpv, Warts
Interventions
Quadrivalent HPV for types 6, 11, 16 and 18
Biological
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
9 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild or Moderate Hepatic Impairment on the Multiple-Dose Pharmacokinetics of Ozanimod

NCT04639115
View directory record Official record
Conditions
Liver Diseases, Digestive System Diseases
Interventions
Ozanimod
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 75 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

NCT03499808
View directory record Official record
Conditions
Amorphous, Eosinophilic, and Acellular Deposit, Constipation, Diarrhea, Early Satiety, Gastrointestinal Hemorrhage, Hepatomegaly, Lymphadenopathy, Macroglossia, Nausea, Primary Systemic Amyloidosis, Purpura, Recurrent Primary Amyloidosis, Refractory Primary Amyloidosis
Interventions
Isatuximab, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
345
States / cities
Anchorage, Alaska • Hot Springs, Arkansas • Burbank, California + 234 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 17, 2026, 5:15 AM EDT
Recruiting Phase 2 Interventional

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

NCT06503146
View directory record Official record
Conditions
Sarcoma, Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC), Mesothelioma, Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Ductal Adenocarcinoma, Ovarian Cancer, Hepatocellular Carcinoma, Gastric Cancer, Cholangiocarcinoma, Bladder Cancer
Interventions
[18F]FAPI-74, [18F]FDG
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

Postoperative Thoracic Epidural Analgesia Versus Intravenous Patient-Controlled Analgesia For Liver and/or Pancreas

NCT01438476
View directory record Official record
Conditions
Liver Cancer, Pancreatic Cancer
Interventions
Intravenous Patient-Controlled Analgesia (IVPCA), Thoracic Epidural Analgesia (TEA), Questionnaires, Pain Assessment
Procedure · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1 Interventional

Pazopanib to Treat Adults With Advanced Cancers and Varying Degrees of Liver Function

NCT00674024
View directory record Official record
Conditions
Neoplasms, Lymphoma
Interventions
Pazopanib, Pazopanib (GW786034)(GW786034)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 110 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 3 Interventional

Nolatrexed Dihydrochloride Compared With Doxorubicin in Treating Patients With Recurrent or Unresectable Liver Cancer

NCT00012324
View directory record Official record
Conditions
Liver Cancer
Interventions
doxorubicin hydrochloride, nolatrexed dihydrochloride
Drug
Lead sponsor
Eximias Pharmaceutical
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
38
States / cities
Tucson, Arizona • Little Rock, Arkansas • Beverly Hills, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced Sep 17, 2026, 5:15 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Novel MRE Technique to Assess a Risk Factor for Liver Cancer

NCT05165446
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
Not listed
Lead sponsor
Natalie Torok
Other
Eligibility
18 Years to 99 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer

NCT03695250
View directory record Official record
Conditions
Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
Interventions
IDO1 Inhibitor BMS-986205, Nivolumab
Drug · Biological
Lead sponsor
Edward Kim
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1 Interventional

Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases

NCT02602327
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer, Liver Metastases
Interventions
Tas-102, SIR-Sphere
Drug · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2022 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1 Interventional

A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver

NCT00001576
View directory record Official record
Conditions
Colorectal Neoplasm, Liver Neoplasm, Neoplasm Metastasis
Interventions
Melphalan, Floxuridine, Leucovorin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection

NCT00513461
View directory record Official record
Conditions
Adult Primary Liver Cancer, Hepatitis C Infection
Interventions
S-adenosyl-L-methionine disulfate p-toluene-sulfonate, placebo, laboratory biomarker analysis, immunoenzyme technique, high performance liquid chromatography
Drug · Other
Lead sponsor
Chao Family Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
5
States / cities
Tucson, Arizona • Long Beach, California • Los Angeles, California + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional

Radiofrequency Ablation Followed By Hepatic Artery Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver

NCT00004142
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
Floxuridine, Fluorouracil (5-FU), Conventional surgery, Radiofrequency ablation
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Phase 1 Interventional

Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer

NCT02323906
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
CC-122, Sorafenib
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
8
States / cities
San Francisco, California • Gainesville, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2017 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein

NCT02435433
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Ramucirumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
8
States / cities
Daly City, California • Los Angeles, California • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Not applicable Interventional

Auriculo-Nerve Stimulation on Post-Operative Opioid Requirement

NCT05506878
View directory record Official record
Conditions
Opioid Use, Auriculotherapy, Pain, Abdominal, Cancer Pain, Liver Transplant
Interventions
NSS-2 BRIDGE, Sham NSS-2 BRIDGE
Device
Lead sponsor
Jacques E. Chelly
Other
Eligibility
18 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
4
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional

Study of the Litx™ System Combined With Chemotherapy in Patients With Colorectal Liver Metastases

NCT00083785
View directory record Official record
Conditions
Liver Metastasis, Colorectal Neoplasms, Liver Neoplasms, Neoplasm Metastasis
Interventions
Talaporfin sodium (LS11), LED-based light infusion device, Light emitting diodes (LED), Photodynamic therapy, Phototherapy, Chemotherapy
Drug · Device · Procedure
Lead sponsor
Light Sciences LLC
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 10, 2007 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Not applicable Interventional Results available

Ablation Confirmation Study

NCT03753789
View directory record Official record
Conditions
Cancer of the Liver, Liver Cancer, Neoplasms, Liver
Interventions
Microwave Ablation
Device
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
22 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Loma Linda, California • Los Angeles, California • Sylmar, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Sep 17, 2026, 5:15 AM EDT
Completed No phase listed Observational

Advanced Endoscopy During COVID-19

NCT04385147
View directory record Official record
Conditions
Cholangitis, Secondary Biliary, Cholangiocarcinoma, Obstructive Jaundice, Pancreas Cancer, COVID-19, SARS-CoV-2
Interventions
Endoscopic management according to standard of care
Other
Lead sponsor
Al-Azhar University
Other
Eligibility
Not listed
Enrollment
670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Albertson, New York
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Intra-arterial Chemotherapy With Cisplatin and Mitomycin-C in Patients With Hepatocellular Carcinoma

NCT00183885
View directory record Official record
Conditions
Hepatocellular Carcinoma, Liver Cancer
Interventions
mitomycin-c, cisplatin
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Sep 17, 2026, 5:15 AM EDT
Completed No phase listed Observational

DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)

NCT04825834
View directory record Official record
Conditions
Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Bladder Cancer, Kidney Cancer, Stomach Cancer, Colorectal Cancer, Pancreas Cancer, Liver Cancer, Skin Cancer
Interventions
Blood Sample Collection
Other
Lead sponsor
Delfi Diagnostics Inc.
Industry
Eligibility
50 Years and older
Enrollment
2,992 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
56
States / cities
Homewood, Alabama • Peoria, Arizona • Fayetteville, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Sep 17, 2026, 5:15 AM EDT
Recruiting Phase 1Phase 2 Interventional

Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

NCT02174549
View directory record Official record
Conditions
Hepatocellular Carcinoma, Gastrointestinal Cancer Metastatic, Neuroendocrine Tumors
Interventions
Tirapazamine, Conventional Transarterial Embolization (TAE)
Drug · Procedure
Lead sponsor
Teclison Ltd.
Industry
Eligibility
20 Years to 99 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
2
States / cities
Palo Alto, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Phase 2 Interventional

Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant

NCT05103904
View directory record Official record
Conditions
Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
Interventions
Laboratory Biomarker Analysis, Lenvatinib
Other · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 17, 2026, 5:15 AM EDT